The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.
 
Merve Kaya
No Relationships to Disclose
 
Nanda Horeweg
Research Funding - Varian Medical Systems (Inst)
 
Alexandra Leary
Honoraria - Medscape
Consulting or Advisory Role - Apmonia Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD (Inst); PEGASCY; Tesaro (Inst); zentalis
Research Funding - Inivata (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Tesaro
 
Stephen Welch
Honoraria - Eisai; GlaxoSmithKline; Merck
Consulting or Advisory Role - Amgen; Eisai
 
Stefan Kommoss
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD
Consulting or Advisory Role - GlaxoSmithKline; MSD; Roche
Research Funding - GlaxoSmithKline (Inst)
 
Nicola Weidner
No Relationships to Disclose
 
Francesco Fanfani
Consulting or Advisory Role - MSD
Travel, Accommodations, Expenses - Stryker
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; Genmab; GlaxoSmithKline; ImmunoGen; MSD; PharmaMar; Seagen
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup
 
John McGrane
Honoraria - Astellas Oncology; BMS GmbH & Co. KG; GlaxoSmithKline; Ipsen; Merck; Pfizer
Consulting or Advisory Role - BMS GmbH & Co. KG; GlaxoSmithKline; Ipsen; Merck; MSD; Pfizer
Speakers' Bureau - BMS GmbH & Co. KG; Eisai; Ipsen; Merck; Pfizer
Travel, Accommodations, Expenses - Ipsen
 
Toon Van Gorp
Consulting or Advisory Role - AstraZeneca (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst); Seagen (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)
 
Ingrid Boere
Consulting or Advisory Role - AstraZeneca (Inst); Tesaro/GSK (Inst)
Research Funding - GlaxoSmithKline (Inst)
 
Anneke M. Westermann
No Relationships to Disclose
 
Joan B. Heijns
No Relationships to Disclose
 
Hein Putter
No Relationships to Disclose
 
Karen Verhoeven-Adema
No Relationships to Disclose
 
Vincent T.H.B.M. Smit
No Relationships to Disclose
 
Carien L. Creutzberg
Consulting or Advisory Role - Merck (Inst)
Research Funding - Elekta (Inst); Varian Medical Systems (Inst)
 
Tjalling Bosse
No Relationships to Disclose
 
Judith R. Kroep
Consulting or Advisory Role - AstraZeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MDS (Inst); Novartis (Inst); Vitroscan (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Philips Research (Inst)